Denise Scots-Knight

Cerimon Pharmaceuticals, Inc. developed and distributed biopharmaceutical products. It developed Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, included pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. The company was founded by Paul J. Sekhri, Ansbert Gadicke, and Luke Evnin in November 2004 and was headquartered in South San Francisco, CA.

Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria.

Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden.

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Part of Mereo BioPharma Group Plc, Mereo Biopharma 3 Ltd. develops bio pharm products. The company is based in London, UK.

Part of Mereo BioPharma Group Plc, Mereo BioPharma 2 Ltd. is a British company that provides research and experimental development for biotechnology. The company is based in London, UK and was founded in 2015.

Nomura International Plc provides a variety of financial services including advisement, investment banking and asset management. It trades in and sells fixed income and equity products, including related derivatives; and provides investment banking services, and corporate finance and private equity services. The company is also involved in asset and principal finance business. It offers investment advisory and management, custody, and employment services. Nomura International was founded in 1981 and is headquartered in London, the United Kingdom.

Part of Mereo BioPharma Group Plc, Mereo BioPharma 4 Ltd. is a British biotechnology company founded in 2017 that provides research and development services. The company is based in London, UK.